trending Market Intelligence /marketintelligence/en/news-insights/trending/iqz9M0Yy7LXH1Iapl67MDw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Proteostasis, Roche's Genentech sign licensing deal worth approximately $100M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Proteostasis, Roche's Genentech sign licensing deal worth approximately $100M

Proteostasis Therapeutics Inc. has agreed to grant the licensing rights of an undisclosed target to Roche Holding AG's unit Genentech Inc. for over $100 million including up-front and milestone payments.

According to Proteostasis Therapeutics, the agreement will not include its cystic fibrosis transmembrane conductance modulators, which were granted fast-track designation by the U.S. Food and Drug Administration in April, and other programs and medicines related to cystic fibrosis. Cystic fibrosis is a rare and inherited disease characterized by the buildup of sticky mucus in the lungs and digestive system, which leads to persistent lung infections and other complications.

Under the agreement, Genentech will bear future research and development costs related to the program, and Proteostasis Therapeutics will receive royalties. The companies have not disclosed the full financial terms, target program or disease areas of focus.

Cambridge, Mass.-based Proteostasis Therapeutics develops small molecule therapeutics that can address malfunctions in protein handling processes within the cells, which can cause a wide range of diseases, including cancer.